Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, announced Tuesday that it has signed an additional agreement with KGK Science to further study the anti-inflammatory nature of its proprietary Amanita muscaria extract AME-1.
"This is a key first step in the health and wellness studies of AME-1, which lay the groundwork for future preclinical research," Brian Tancowny, who is the scientific advisor to Psyched Wellness said in a statement.
The Toronto-based company noted that its contract research organization (CRO) partner, KGK Science specializes in nutraceutical product testing and development and is leading the pre-clinical trials for Psyched.
READ: Psyched Wellness submits patent application for AME-1
Psyched said the new agreement with its CRO partner will “further advance” the preliminary findings, indicating an anti-inflammatory property of the AME-1 extract.
“This study will be the first to further explore the anti-inflammatory nature of the AME-1 extract from the Amanita Muscaria mushroom with a particular focus on gut health,” said the company in a statement. When gut health is damaged, it can lead to inflammation, thus promoting a chronic condition of the gut lining and impairment of barrier function of the digestive tract, according to the company.
The aim of the study is to explore the anti-inflammatory properties of AME-1 extract and demonstrate activities that may enhance digestive barrier function and immunity. “This is significant as gut health and immunity promotion is substantial for health and wellness,” added the company.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive